Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
NESS ZIONA, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ:SLGL), ("Sol-Gel"), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present an overview of the Company and provide a business update at the following virtual investor conferences.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Raymond James Institutional Investors Conference
| Speakers: | Dr. Alon Seri-Levy, Chief Executive Officer |
| Date: | 8:20 AM ET on March 1, 2021 |
| Access: | Available to conference participants. |
H.C. Wainwright Global Life Sciences Conference
| Speakers: | Gilad Mamlok, Chief Financial Officer |
| Date: | March 9-10, 2021 |
| Access: | Available on demand to conference participants. |
A webcast replay of the presentation at H.C. Wainwright Life Sciences Conference will be available in the Investors/Events and Presentations section of the Company's website at www.sol-gel.com for 30 days.
About Sol-Gel Technologies
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo (benzoyl peroxide and tretinoin) cream, under investigation for the treatment of acne vulgaris, and Epsolay®, under investigation for the treatment of papulopustular rosacea. The Company's pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment of palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.
For further information, please contact:
Sol-Gel Contact:
Gilad Mamlok
Chief Financial Officer
+972-8-9313433
Investor Contact:
Michael Levitan
Solebury Trout
+1-646-378-2920
mlevitan@soleburytrout.com
Source: Sol-Gel Technologies Ltd.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.